BPCA adverse event reporting
Executive Summary
FDA will update the subcommittee on adverse event reporting for several products as mandated by the Best Pharmaceuticals for Children Act on June 12. AE reporting will be detailed for Pfizer's Zoloft (sertraline) and Alza's Ditropan (oxybutynin). An interim update will be presented on Pfizer's Lipitor (atorvastatin) and Merck's Zocor (simvastatin). The committee heard a preliminary presentation on Zoloft in March (1"The Pink Sheet" March 31, p. 9) The meeting will begin at 8:30 a.m. on June 11 at the Holiday Inn in Gaithersburg, Md. On June 12, the discussion on adverse event reporting will start at 3:15 p.m. after the committee meets in closed session...
You may also be interested in...
Pediatric Adverse Event Analysis By FDA Will Project Incidence Rates
FDA plans to use hospital use data to project use among the in-patient pediatric population to determine incidence rates for adverse event reports mandated by the Best Pharmaceuticals for Children Act
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.